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I.  PRD	RISK	TITLE:	RISK	OF	RENAL	STONE	FORMATION	
Description:		Kidney	stone	formation	and	passage	has	the	potential	to	greatly	impact	mission	success	and	crewmember	health	for	long-duration	missions.	Alterations	in	hydration	state	(relative	dehydration),	spaceflight-induced	changes	in	urine	biochemistry	(urine	super-saturation),	and	bone	metabolism	(increased	calcium	excretion)	during	exposure	to	microgravity	may	increase	the	risk	of	kidney	stone	formation.	It	is	unclear	what	mitigation	strategies	would	be	the	most	effective	in	addressing	this	risk.		
II.  EXECUTIVE	SUMMARY		The	formation	of	renal	stones	poses	an	in-flight	health	risk	of	high	severity,	not	only	because	of	the	impact	of	renal	colic	on	human	performance	but	also	because	of	complications	that	could	potentially	lead	to	crew	evacuation,	such	as	hematuria,	infection,	hydronephrosis,	and	sepsis.	Evidence	for	risk	factors	comes	from	urine	analyses	of	crewmembers	,	documenting	changes	to	the	urinary	environment	that	are	conducive	to	increased	saturation	of	stone-forming	salts,	which	are	the	driving	force	for	nucleation	and	growth	of	a	stone	nidus.	Further,	renal	stones	have	been	documented	in	astronauts	after	return	to	Earth	and	in	one	cosmonaut	during	flight.	Biochemical	analysis	of	urine	specimens	has	provided	indication	of	hypercalciuria	and	hyperuricemia,	reduced	urine	volumes,	and	increased	urine	saturation	of	calcium	oxalate	and	calcium	phosphate.			A	major	contributor	to	the	risk	for	renal	stone	formation	is	bone	atrophy	with	increased	turnover	of	the	bone	minerals.	Dietary	and	fluid	intakes	also	play	major	roles	in	the	risk	because	of	the	influence	on	urine	pH	(more	acidic)	and	on	volume	(decreased).	Historically,	specific	assessments	on	urine	samples	from	some	Skylab	crewmembers	indicated	that	calcium	excretion	increased	early	in	flight,	notable	by	day	10	of	flight,	and	almost	exceeded	the	upper	threshold	for	normal	excretion	(300mg/day	in	males).	Other	crewmember	data	documented	reduced	intake	of	fluid	and	reduced	intake	of	potassium,	phosphorus,	magnesium,	and	citrate	(an	inhibitor	of	calcium	stone	formation)	in	the	diet.	Hence,	data	from	both	short-duration	and	long-duration	missions	indicate	that	space	travel	induces	risk	factors	for	renal	stone	formation	that	continue	to	persist	after	flight;	this	risk	has	been	documented	by	reported	kidney	stones	in	crewmembers.			
III. INTRODUCTION	Nephrolithiasis	is	the	condition	marked	by	the	development	of	renal	stones.	Renal	stones	are	aggregates	of	crystals	that	are	formed	in	urine	that	is	supersaturated	in	terms	of	its	salt	components.	Hypercalciuria,	a	characteristic	of	the	skeletal	adaptation	to	space,	contributes	to	the	increased	supersaturation	of	urine,	with	elevations	of	calcium	phosphate	or	calcium	oxalate.	However,	whether	a	renal	stone	forms	in	supersaturated	urine	depends	upon	other	risk	factors.	The	presence	of	these	aggregates	in	the	renal	collection	or	excretion	system	can	potentially	result	in	stone	formation,	renal	colic,	hematuria,	infection	or	sepsis,	and	can	obstruct	urine	flow	to	cause	hydronephrosis.	A	renal	stone	formed	during	a	spaceflight	mission	could	cause	acute	illness	with	crewmember	functional	impairment,	negative	mission	impact,	or	even	significant	morbidity	or	mortality	for	the	afflicted	crewmember.			
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To	date,	there	has	been	one	reported	episode	of	nephrolithiasis	during	spaceflight,	where	a	cosmonaut	experienced	severe	lower	abdominal	pain	that	spontaneously	resolved,	later	attributed	to	renal	colic	(Lebedev	1990).	A	previous		survey	of	renal	stones	in	US	astronauts	has	revealed	a	total	of	14	episodes	of	kidney	stones	(Pietrzyk	et	al.	2007);	some	of	these	episodes	occurred	in	the	pre-flight	period	(n=5)	with	the	balance	(n=9)	having	occurred	in	the	post-flight	phase.	The	time	period	for	the	onset	of	symptomatic	stone	formation	following	return	ranged	from	9-120	months	after	landing.	Six	of	the	nine	post-flight	episodes	had	occurred	after	1994,	corresponding	with	the	extension	of	Space	Shuttle	mission	length	to	12	days	duration.	A	total	of	12	astronauts	have	experienced	nephrolithiasis,	with	two	astronauts	reporting	multiple	episodes;	both	male	(n=10)	and	female	(n=2)	astronauts	have	been	afflicted.		Given	the	severity	of	the	risk	for	renal	stone	formation,	it	is	important	to	characterize	the	spaceflight	conditions	that	promote	nephrolithiasis	in	order	to	take	appropriate	steps	to	mitigate	this	risk.	The	primary	risk	factors	for	renal	stone	formation	in	space	are	the	increased	excretion	of	calcium	due	to	bone	atrophy	and	lower	urine	output	associated	with	the	microgravity	environment.	Other	contributing	risk	factors	include	dehydration,	diet	(high	sodium,	high	animal	proteins),	low	urinary	citrate,	genetics,	and	environmental	derangements	(for	example,	alterations	in	ambient	temperatures).		These	factors	can	contribute	to	increased	urinary	supersaturation	of	salts,	low	urine	pH,	and	reduced	urine	volumes,	which	are	all	favorable	conditions	for	crystallization.				Renal	stones	come	in	different	types,	including	calcium	oxalate,	uric	acid,	struvite,	cysteine,	and	brushite	(calcium	phosphate)	stones.	The	formation	of	a	specific	stone-type	depends	upon	the	presence	of	particular	risk	factors.	The	most	common	renal	stone,	and	a	main	component	in	stones	of	mixed	composition,	is	calcium	oxalate.	This	stone	type	is	commonly	caused	by	treatable	metabolic	disorders	of	hypercalciuria	and	is	associated	with	multiple	simultaneous	stone	formation	or	stone	recurrence,	inducing	pain	with	both	passage	and	obstruction	(Figure	1).	Similar	to	calcium	oxalate	stones,	uric	acid	stones	induce	the	same	adverse	effects	but	occur	at	decreased	incidence,	responsible	for	only	5%	of	renal	stones.	Uric	acid	stones	are	also	translucent	and,	unlike	the	other	stones,	cannot	be	distinguished	by	radiographic	imaging.	Struvite	stones	are	generated	by	infections	of	urease-containing	microorganisms	that	are	capable	of	hydrolyzing	the	urea	in	urine	to	carbon	dioxide	and	ammonia.	When	urine	pH	exceeds	7.2,	struvite	stones	may	form,	and	the	resulting	obstruction	can	fill	the	renal	collection	system	and	erode	into	the	renal	tissue.	Treatment	is	by	surgical	removal	unless	stone	size	is	<2	cm	where	lithotripsy	can	be	applied	to	fragment	the	stone.	Unlike	other	renal	stones,	cystine	stones	have	a	single	etiology,	hereditary	cystinuria;	with	this	condition,	stone	formation	begins	in	childhood,	and	stones	may	grow	large	enough	to	fill	the	renal	collection	system.	Finally,	brushite	is	the	name	for	a	calcium	phosphate	stone,	the	formation	of	which	is	promoted	by	high	urine	pH	and	supersaturation	of	urine	with	the	calcium	phosphate	salt.	Just	as	on	Earth,	it	is	more	cost	effective	to	prevent	stone	formation	during	a	spaceflight	mission	than	it	is	to	treat	a	crewmember	(Parks	and	Coe	1996).	Thus,	understanding	the	etiology	for	the	formation	of	specific	stone	types	and	identifying	which	stones	are	more	likely	to	be	formed	during	spaceflight	missions	will	direct	the	application	of	appropriate	countermeasures	for	nephrolithiasis.	
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Figure	1.		Microphotographs	of	a	calcium-containing	renal	stones		Diagnosing	nephrolithiasis	is	not	as	difficult	as	distinguishing	the	type	of	renal	stone.	It	may	be	possible	to	delineate	stones	by	physical	features.	Oxalate,	cystine	and	struvite	stones	have	distinctive	appearances	(mimicking	stars,	wax-like	eggs,	and	tree	roots,	respectively),	but	final	diagnosis	requires	recovery	of	the	stone	itself,	which	is	not	always	possible.	Laboratory	evaluations	can	be	used	to	determine	risk	factors	for	stone	formation	based	upon	saturation	levels	of	calcium,	oxalate,	and	uric	acid	measured	in	24-hour	urine	specimens.	However,	assessment	of	pH,	urine	volumes,	urine	citrate	levels	(an	inhibitor	of	stone	formation),	creatinine	levels	(a	marker	of	optimal	renal	function),	and	serum	calcium	levels	can	provide	evidence	of	whether	conditions	are	conducive	to	stone	formation.	If	hypercalcemia	is	detected,	then	assay	of	parathyroid	hormone	can	be	used	to	diagnose	the	existence	of	a	metabolic	disorder	that	may	be	at	fault.		Additionally,	if	conditions	that	favor	increased	urine	saturation	and	stone	formation	are	detected,	countermeasure	approaches,	specific	for	stone	type,	can	be	implemented.	For	example,	treating	hypercalciuria	(>300mg/day	in	males,	>250mg/day	in	females)	requires	identifying	and	addressing	the	cause	of	increased	urinary	calcium.	Pharmacological	agents,	such	as	thiazide	diuretics,	or	dietary	adjustments	can	suppress	bone	atrophy	or	promote	renal	calcium	reabsorption.	Avoiding	foods	high	in	oxalate	(nuts,	pepper,	chocolate,	rhubarb,	spinach,	dark	green	vegetables,	fruits)	and	diets	high	in	fat	will	reduce	hyperoxaluria	(>75-150mg/day).	At	Johnson	Space	Center,	<45mg/day	of	urine	oxalate	is	considered	in	the	range	of	decreased	risk	and	anything	over	45mg/day	prompts	consideration	of	increased	risk.	Reducing	the	ingestion	of	purine-containing	foods,	such	as	most	meats,	will	suppress	hyperuricosuria.	Ingesting	an	oral	alkali	such	as	potassium	citrate	will	suppress	calcium	oxalate	crystallization	by	raising	urine	pH	and	provide	an	inhibitor	of	crystal	aggregation	and	growth	by	binding	the	calcium	ion	to	form	the	soluble	calcium	citrate.	Increasing	fluid	intake	to	increase	urine	volume	can	dilute	the	urinary	risk	factors	to	bring	these	factors	under	the	upper	limit	of	metastability	for	solubility	of	the	stone-forming	salts	(Whitson	et	al.	2001b).	Even	persons	homozygous	for	cystinuria	(and	therefore	at	high	risk	of	cysteine-stone	formation)	can	dilute	out	the	concentration	of	cystine	by	high	fluid	intake,	thereby	reducing	their	personal	risk	for	stone.	Unfortunately,	given	the	constraints	of	mission	operations,	the	indiscriminate	application	of	all	these	countermeasures	would	not	be	an	effective	approach	to	risk	management.	Instead,	the	full	understanding	of	the	risk	factors	incurred	during	missions	in	space	and	knowledge	of	the	
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incidence	of	renal	stone	types	is	warranted	in	order	to	make	judicious	selection	of	prophylactic	approaches.		Recent	medical	research	has	highlighted	an	additive	effect	of	potassium	citrate	beyond	the	risk	of	stone	formation.	One	study	demonstrated	a	positive	association	between	the	ingestion	of	potassium	citrate	and	increased	bone	density	(Pak	et	al.	2002).	Potassium	citrate	may	also	prevent	bone	loss	by	providing	an	alkali	load,	averting	the	bone-resorbing	effect	of	sodium	chloride	excess	(Sellmeyer	et	al.	2002).	There	is	also	evidence	that	potassium	citrate	can	reduce	bone	loss	in	postmenopausal	women,	as	revealed	by	decreases	in	bone	resorption	biomarkers,	possibly	by	counteracting	the	deleterious	effect	of	acidemia(Marangella	et	al.	2004).	Potassium	citrate	also	improves	calcium	balance	among	patients	with	distal	renal	tubular	acidosis,	both	by	increasing	intestinal	calcium	absorption	and	by	mitigating	calcium	excretion	(Preminger	et	al.	1987).		This	report	will	highlight	the	risk	for	renal	stone	formation	in	space	by	outlining	the	characterization	of	risk	factors	as	determined	in	crewmembers	after	short-duration	spaceflight	missions	aboard	the	Space	Shuttle.	Published	flight	data	document	some	of	the	environmental	and	dietary	contributors	to	renal	stone	formation,	including	high	animal	protein	intake	and	high	acid	load.	As	mentioned	above,	risk	factors	for	stone	formation	during	spaceflight	include	increased	calcium	excretion	due	to	net	bone	resorption	and	low	urine	volume.	Thus,	the	risk	for	renal	stone	formation	is	intimately	linked	to	hypercalciuria	induced	by	the	unbalanced	bone	resorption	during	the	uncoupled	bone	remodeling	in	space.			
IV.  EVIDENCE		
A.  Spaceflight	Evidence	The	results	from	specimens	obtained	from	crewmembers	who	have	flown	in	space	detail	the	biochemical	and	environmental	risk	factors	associated	with	the	risk	for	renal	stone	formation	during	and	after	spaceflight.	Data	sources	are	described	below.		
1. Historical	Data	from	Skylab	Specific	assessments	in	some	Skylab	crewmembers	indicated	that	calcium	excretion	increased	early	in	flight,	notable	by	day	10	of	flight,	and	almost	exceeded	the	upper	threshold	for	normal	excretion	(300mg/day	in	males)	in	some	crewmembers	during	Skylab	missions	(Figure	2).			
Risk of Renal Stone Formation 
8 
 
	
Figure	2.	Calcium	balance	during	and	after	Skylab	missions.	Adapted	from	Rambaut	and	Johnston	(1979)	
	
2. Short-duration	spaceflight	missions	on	the	Space	Shuttle		Retrospective	analysis	of	urinary	data	from	U.S.	Space	Shuttle	crewmembers	was	conducted	in	24-hour	urine	specimens	collected	10	days	pre-launch	(~L-10	day)	and	immediately	post-landing.	Analysis	consisted	of	urine	characteristics	associated	with	renal	stone	formation	and	relative	supersaturation	of	stone-forming	constituents.	All	pre-	and	post-flight	data	from	Space	Shuttle	crewmembers	are	tabulated	below	(Tables	1-3).		
Table	1.		Mean	Values	for	Urinary	Biochemical	Parameters	in	Crewmembers	after	Short-Duration	Spaceflight												
Parameter	 Pre-flight	
(n=332)	 Post-flight	(n=329)	 P	value	 Normal	Reference	
Values*	Total	Volume	(L/d)	 2.1	±	0.06	 2.0	±	0.06	 NS	 2-2.5	<1	L/d		 13.0%	 13.1%	 	 -	<1-2	L/d		 38.9%	 46.2%	 	 -	>2	L	d																														 48.2%	 40.7%	 	 -	Oxalate	(mg/d)	 38	±	0.9														 37	±	0.9	 NS	 0-45		Calcium	(mg/d)	 183	±	5.3		 	234	±	6																	 <0.05	 <300	M	<250	F	pH	 6.05	±	0.02										 5.79	±	0.03												 <0.05	 4.5-8.0	Citrate	(mg/d)																		714	±	16														 629	±	18																 <0.05	 >	320	Magnesium	(mg/d)	 116.0	±	2.5	 99.0	±	2.2															 NS	 75-120	Values	are	Mean	±	SEM;	L/d	–	liters	per	day.		Pre-flight	urines	collected	10	days	before	launch	and	post-flight	urines	collected	on	landing	following	missions	of	<16	days.		*Johnson	Space	Center	Clinical	Laboratory	and	Johnson	Space	Center	Cellular	and	Biomedical	Laboratory.		
Table	2.		Mean	Values	for	Relative	Saturation	of	Stone-Forming	Salts	in	Urine	from	Crewmembers	during	Short-Duration	Spaceflight				 														
Parameter			 Pre-flight	n=332	 	 Post-flight																n=329	 P	value		 Normal		Reference		
Value	Calcium	Oxalate	 1.53	±	0.06	 2.26	±	0.07	 	<0.05	 <	2.0	Brushite	 1.25	±	0.06									 1.00	±	0.06	 	<0.05	 <	2.0	Sodium	urate																			 	2.41	±	0.11									 1.42	±	0.07	 <0.05	 <	2.0	Struvite	 3.05	±	0.83									 3.69	±	2.21													 NS	 <	75.0	uric	H+																														 1.69	±	0.08										 2.27	±	0.09										 <0.05	 <	2.0	
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Values	are	Mean	±	SEM.	The	relative	urinary	supersaturations	are	unitless	ratios	determined	from	the	activity	product	of	the	various	concentrations	of	the	urinary	chemical	composition	and	represent	the	saturation	of	the	stone-forming	salts	and	the	concentration	of	the	undissociated	uric	acid.		The	supersaturation	data	are	expressed	relative	to	the	values	from	normal	non-stone	forming	subjects	and	indicate	the	state	of	urinary	supersaturation,	a	fundamental	requirement	for	stone	formation.		Urinary	supersaturation	values	<2.0	indicate	a	decreased	risk	for	calcium	oxalate,	brushite,	sodium	urate	and	uric	acid	stone	formation.		Values	<75.0	reflect	a	decreased	risk	for	struvite	stones.		
Table	3.		Prevalence	of	Biochemical	Abnormalities	in	Urine	in	Astronauts	Before	and	Following	Short-Duration	Spaceflight		
Abnormality	 Pre-flight	 Post-flight		Hypercalciuria	(>250	mg/d)	 20.8%																			38.9%	Hypocitraturia	(<320	mg/d)							 6.9%	 14.6%	Hypomagnesuria	(<60	mg/d)				 6.0%																		15.8%	Urinary	supersaturation	(>2.0)	 	 	Calcium	oxalate	 25.6	%	 46.2	%	Uric	Acid	 32.8	%	 48.6	%	Brushite	 19.3	%	 13.1	%	Sodium	urate	 44.9	%	 25.8	%		
Table	4.		Urinary	Tract	Stone	Events	in	the	Astronaut	Corps	(as	of	mid-2016)	Time	 #	of	Events	 Comments	Prefight	 5	 Before	flight,	no	previous	flight	experience	R+0	to	90	days	 1	 	R+90	to	180	days*	 3	 	R+180	to	270	days*	 1	 	R+270	to	360	days	*	 2	 	Inter-flight	 4	 Greater	than	360	days	post-flight,	but	flew	again	R	>	360	days	(Active)	 2	 Greater	than	360	days	and	never	flew	again	Post	NASA	Career	 19	 	Total		 37	 	All	U.S.	Astronauts	(n=357).	Total	number	of	crewmembers	reporting	events	=	37.	*No	cases	in	this	interval	reported	pre-flight	events.	R+:	number	of	days	post-flight.	Post	NASA	Career	=	event	occurred	following	retirement	from	active	astronaut	duty.		In	a	series	of	investigations	led	by	Peggy	Whitson,	Ph.D,	environmental	and	biochemical	risk	factors	for	renal	stone	formation	were	extensively	characterized	for	both	short-	and	longer-duration	missions.	It	was	first	reported	that	an	increased	risk	of	calcium	oxalate	and	uric	acid	stone	formation	was	evident	immediately	after	spaceflight,	concurrent	with	the	hypercalciuria	and	hypocitraturia	quantified	after	return	(Whitson	et	al.	1993).	Further	investigation,	which	included	analysis	of	urine	collected	during	flight,	revealed	that	many	of	the	contributing	factors	to	renal	stone	formation	associated	with	spaceflight	were	related	to	nutrition,	urinary	pH,	and	volume	output	(Whitson	et	al.	1997).	In	addition,	biochemical	analysis	of	urine	specimens	obtained	during	longer	Space	Shuttle	missions	provided	a	temporal	reflection	of	the	risk,	indicating	that	the	increased	risk	for	renal	stone	formation	occurs	rapidly	during	spaceflight,	continues	throughout	the	mission,	and	persists	following	landing	(Whitson	et	al.	1999).	In-flight	evidence	from	Space	Shuttle	missions	associated	urinary	supersaturation	and	decreased	urine	excretion	with	reduced	fluid	intake;	further,	increasing	the	volume	of	urine	output	effectively	reduced	the	urine	
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supersaturation	risk	(Whitson	et	al.	2001b).		However,	the	use	of	this	approach	as	an	in-flight	countermeasure	may	not	address	all	risk	factors	during	a	spaceflight	mission.	Figure	3a	(pre-flight)	and	3b	(post-flight)	displays	the	relative	risk	of	stone	formation	in	a	representative	crewmember	of	a	Space	Shuttle	flight.	Note	that	the	increased	post-flight	risk	for	stone	formation	(Figure	3b)	corresponded	with	a	larger	excretion	of	calcium	and	a	reduction	in	pH	(metabolic	factors),	with	a	reduction	in	total	urine	volume	and	increased	levels	of	sulfate	(hydration	and	dietary	factors),	and	with	greater	urine	saturation	for	stone-forming	salts	(sodium	urate,	calcium	oxalate,	brushite,	and	uric	acid	stones).		
 
Figure	3a	Representative	pre-flight	renal	stone	risk	profile	determined	in	a	single	crewmember	before	a	short-duration	flight	(i.e.	Space	Shuttle).	Blue	bars	represent	decreased	risk,	red	bars	represent	increased	risk.	
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Figure	3b.	Representative	post-flight	renal	stone	risk	profile	determined	in	the	same	crewmember	immediately	following	a	short-duration	flight	(i.e.,	Space	Shuttle).		Blue	bars	represent	decreased	risk,	red	bars	represent	increased	risk.		As	presented	in	the	2008	Evidence	Report	on	the	Risk	of	Renal	Stone	Formation	(Sibonga	et	al.	2008),	a	retrospective	chart	review	for	stone	formation	in	U.S.	astronauts	identified	fourteen	cases	of	renal	stone	formation	occurring	in	twelve	different	astronauts,	with	nine	of	those	episodes	occurring	in	the	post-flight	period	(n=7	astronauts).	In	addition	to	one	in-flight	stone	formation	in	a	cosmonaut,	one	additional	cosmonaut	has	been	identified	as	forming	multiple	urinary	calculi	(J.A.	Jones;	personal	communication).	Of	the	renal	stones	recovered	from	astronauts	pre-	and	post-flight,	4	stones	were	of	calcium	oxalate,	1	stone	was	of	uric	acid,	1	stone	was	of	mixed	components,	and	9	were	of	unknown	composition.	While	some	of	these	crewmembers	appeared	to	have	a	history	or	predisposition	for	stone	formation	prior	to	spaceflight,	unique	habitability	issues	common	to	spaceflight	and	mission	operations	may	exacerbate	the	risk	for	renal	stone	formation.	These	issues	include	food	stability,	preservation	of	food	using	high	sodium	content,	dehydration,	bone	atrophy,	quantity	of	onboard	water	supplies,	and	limited	nutritional	choices.	It	may	be	possible	to	reduce	this	risk	by	correcting	operational	issues;	however,	depending	upon	the	duration	of	a	specific	mission,	it	may	also	be	prudent	to	formulate	criteria	for	excluding	persons	with	pre-existing	risk	factors	to	reduce	the	potential	impact	to	mission	objectives.			
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3. Long-duration	during	the	Shuttle-Mir	Missions		The	results	from	an	investigation	of	eleven	astronauts	and	cosmonauts	who	flew	on	the	Mir	space	station	provided	evidence	of	the	risk	for	stone	formation	during	long-duration	missions	(Whitson	et	al.	2001a).	Data	from	missions	ranging	from	129-208	days	suggested	spaceflight	and	the	return	to	Earth	have	acute	effects	on	the	urinary	biochemistry	that	may	favor	increased	crystallization	in	the	urine.	Changes	previously	observed	during	short-duration	Space	Shuttle	flights	included	a	rapid	increase	in	the	supersaturation	of	the	stone-forming	salts	in	the	urine	early	during	the	flight	that	continued	through	landing	day.		However,	the	stone-forming	potential	in	the	urine	was	different	during	and	after	spaceflight.	During	flight,	an	increased	risk	occurred	for	both	calcium	oxalate	and	calcium	phosphate	stones.	Immediately	after	flight,	however,	the	risk	was	greater	for	calcium	oxalate	and	uric	acid	stone	development,	which	could	be	attributed	to	low	urine	volumes	and	decreased	urinary	pH.	In	these	long-duration	crewmembers,	there	was	a	47%	decrease	in	urine	volume	early	during	the	missions	(before	flight	day	30)	and	a	39%	lower	urine	output	late	in	the	mission	(after	mission	day	60).	Urinary	calcium	levels	during	the	pre-flight	period	ranged	from	159mg/day	to	316mg/day,	and	during	flight	the	range	was	129mg/day	to	435mg/day.		During	flight,	7	of	the	11	crewmembers	demonstrated	higher	in-flight	urinary	calcium	values	as	compared	to	their	respective	pre-flight	levels,	and	5	of	these	11	crewmembers	exhibited	calcium	excretion	greater	than	250mg/day.	Data	from	these	long-duration	missions	suggested	a	similar	trend,	as	with	short-duration	missions,	showing	increased	risk	for	calcium	phosphate	stone	formation	occurring	early	in	flight.		These	data	suggested	that	the	early	phase	(<30	days)	of	spaceflight	may	generate	conditions	in	which	the	risk	of	stone	formation	was	greater	than	during	the	later	phases	of	the	mission.	These	data	are	consistent	with	the	short-duration	Space	Shuttle	data	in	which	both	calcium	oxalate	and	calcium	phosphate	risk	increased.		
4. International	Space	Station		Finally,	a	flight	experiment	(96-E057)	performed	during	long-duration	missions	(“Renal	stone	risk	during	spaceflight:	Assessment	and	Countermeasure	Evaluation,”	Primary	Investigator	P.	Whitson)	is	collecting	data	from	crewmembers	of	International	Space	Station	(ISS)	missions	(Whitson	2009).	The	aim	of	the	experiment	is	to	evaluate	the	in-flight	efficacy	of	potassium	citrate	as	a	mitigator	of	nephrolithiasis	(particularly	of	stones	composed	of	calcium	salts)	during	long-duration	spaceflight.	Potassium	citrate	is	a	known	therapy	for	the	formation	of	calcium	oxalate,	calcium	phosphate,	and	uric	acid	containing	stones	because	of	the	formation	of	the	soluble	calcium	citrate	complex.	Risk	factors	are	also	alleviated	by	the	alkalization	of	urine	and	by	the	reduction	of	physiological	acid/base	ratio	as	induced	by	potassium	and	the	metabolism	of	citrate	to	carbonate.	In	this	double-blind	study,	crewmember	subjects	on	Expeditions	3-6,	8,	and	11-14	consumed	two	tablets,	either	placebo	or	20mEq	potassium	citrate,	with	their	last	daily	meal	from	L-3	to	R+14	days	(3	days	pre-launch	to	14	days	after	return).	Twenty-four	hour	urine	specimens	were	collected	three	times	during	flight:	early	(<35	days	into	flight),	middle	(between	36-120	days	of	flight),	and	late	mission	(within	30	days	of	undocking	for	return).	The	urinary	biochemistry	was	analysed	and	the		urinary	supersaturation	levels	were	calculated	after	return.	All	diet,	fluid,	exercise	and	medications	were	logged	for	48h	before	and	during	the	urine	collection	
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time	to	assess	any	potential	impact	from	environmental	factors.	In	addition	to	evaluating	the	efficacy	of	potassium	citrate	to	minimize	the	risk	of	stone	formation,	the	results	of	this	experiment	described	the	renal	stone	forming	potential	in	crewmembers	as	a	function	of	time	in	space	as	well	as	the	stone	forming	potential	during	the	post-flight	period.		Results	of	this	investigation	were	briefly	described	above	and	recently	published	(Whitson	et	al.	2009).	As	a	result	of	the	knowledge	gained	in	this	study,	potassium	citrate	as	a	prophylactic	countermeasure	had	been	approved	for	transition	to	medical	operations	by	the	Office	of	the	Chief	Health	and	Medical	Officer.		Possible	side	effects	of	potassium	citrate	supplementation,	although	uncommon,	include	minor	gastrointestinal	complaints	(for	example,	abdominal	discomfort,	vomiting,	diarrhea,	or	nausea)	and	hyperkalemia,	which	may	occur	in	subjects	with	renal	disease,	potassium-sparing	diuretic	ingestion,	or	acute	dehydration.	Upper	gastrointestinal	mucosal	lesions,	including	erosions	and	ulcerations,	have	been	reported	in	association	with	oral	potassium	supplementation;	however,	studies	including	placebo	controls	have	reported	mixed	results	with	no	demonstrated	correlation	between	such	lesions	and	symptomatic	complaints	or	occult	bleeding.	The	risk	of	severe	complications,	such	as	small	bowel	ulceration,	stenosis,	or	gastrointestinal	perforation	is	estimated	at	less	than	1	per	100,000	patient-years	based	on	spontaneous	adverse	reaction	reports	(Gonzalez	et	al.	1998).	These	risks	may	be	minimized	by	providing	slow-release	wax	matrix	tablets,	ingesting	the	dose	with	meals,	ingesting	the	tablet	whole	without	chewing,	crushing,	or	sucking,	limiting	additional	salt	intake,	and	encouraging	high	fluid	intake.	This	agent	has	been	used	prophylactically	during	spaceflight	in	known	stone-forming	astronauts	who	have	received	a	medical	waiver	for	short-duration	missions;	the	efficacy	of	potassium	citrate	supplementation	has	been	demonstrated	in	spaceflight	crews,	as	described	above.	To	date,	potassium	citrate	remains	one	of	the	only	NASA-validated	and	approved	operational	countermeasures	for	spaceflight.			Recent	medical	research	has	highlighted	an	additive	effect	of	potassium	citrate	beyond	the	risk	of	stone	formation,	showing	a	positive	association	between	the	ingestion	of	potassium	citrate	and	increased	bone	density	(Pak	et	al.	2002).	Potassium	citrate	may	also	prevent	bone	loss	by	providing	an	alkali	load,	averting	the	bone	resorbing	effect	of	sodium	chloride	excess	(Sellmeyer	et	al.	2002;	Marangella	et	al.	2004).	Potassium	citrate	has	also	been	shown	to	reduce	bone	loss	in	postmenopausal	women,	as	revealed	by	decreases	in	bone	resorption	biomarkers,	possibly	by	counteracting	the	deleterious	effect	of	academia.	Inhibiting	bone	resorption	associated	with	microgravity	should	also	diminish	the	risk	of	renal	stone	formation.	In	theory,	this	could	also	be	accomplished	by	physical	loading	(for	example,	via	exercise	countermeasures)	or	by	the	use	of	other	pharmaceutical	agents,	such	as	bisphosphonates.		
B.  Ground-Based	Evidence		Similar	to	potassium	citrate,	potassium-magnesium	citrate	is	also	under	clinical	study	and	may	soon	be	approved	as	an	additional	supplement	for	inhibition	of	stone	formation	(Pak	and	Fuller	1986;	Pak	1994;	Whalley	et	al.	1996).	Potassium-magnesium	citrate	was	evaluated	as	a	countermeasure	for	renal	stones	in	a	flight	analog	experiment	(Zerwekh	et	al.	2007).	A	double-blind,	placebo-controlled	study	was	conducted	in	normocalciuric	
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human	test	subjects	skeletally	unloaded	by	five	weeks	of	prolonged	bed	rest	as	an	analog	for	spaceflight.	Two	24h	urine	collections	were	obtained	to	evaluate	renal	stone	risk	parameters	and	the	relative	saturation	of	calcium	oxalate,	brushite,	and	undissociated	uric	acid.	Circulating	parathyroid	hormone	and	vitamin	D	metabolites	were	measured	in	serum	samples.	As	expected,	bed	rest	immediately	induced	hypercalciuria	by	an	increase	of	50mg/day	in	both	groups.	Subjects	treated	with	potassium-magnesium	citrate	displayed	reductions	in	the	relative	saturation	of	calcium	oxalate	and	in	the	concentration	of	undissociated	uric	acid	compared	to	placebo.	Parathyroid	hormone	and	vitamin	D	metabolites	were	reduced	in	both	groups,	with	no	statistical	difference	between	groups	in	the	decrements.	The	study	authors	concluded	that	potassium	magnesium	citrate	is	an	effective	inhibitor	of	renal	stone	formation	as	indicated	by	the	reduced	urine	saturation	of	calcium	oxalate	and	concentration	of	undissociated	uric	acid	by	the	citrate	chelation	of	calcium	and	the	alkalization	of	pH,	respectively	(Zerwekh	et	al.	2007).		
V.  COMPUTER-BASED	SIMULATION	INFORMATION		A	Population	Balance	Equation	model	was	developed	at	NASA	Glenn	Research	Center	for	the	Integrated	Medical	Model	(IMM)	as	a	tool	to	predict	a	steady	state	distribution	of	renal	calculi	size	(calcium	oxalate	crystals)	through	stages	of	nucleation,	growth	and	agglomeration	as	it	moves	in	the	kidney	while	in	microgravity	(Kassemi	and	Thompson	2016a).	The	IMM	is	a	Monte	Carlo	simulation	model	that	explores	the	event	space	for	medical	concerns	during	a	given	reference	mission	(Gilkey	et	al.	2012).	Here,	the	Population	Balance	Equation	model	builds	off	of	the	IMM	capabilities	by	inputting	data	from	the	biochemical	profile	of	astronauts	for	predictions	regarding	the	efficacy	and	influence	of	dietary	countermeasures,	such	as	pyrophosphate,	citrate	supplementation,	and	hydration,	on	renal	stone	formation	(Kassemi	and	Thompson	2016b).		The	model	predictions	suggested	that	some	mitigation	benefit	is	achieved	by	increasing	citrate	levels	from	average	Earth-based	levels,	but	preventing	declines	in	citrate	levels	(i.e.,	maintaining	normal	urine	values)	during	spaceflight	is	as	effective,	if	not	more	a	critical,	mitigation	strategy.		In	addition,	pyrophosphate	has	the	potential	of	shifting	the	maximum	crystal	aggregate	to	a	much	smaller	size	stone,	presumably	one	that	is	safer,	and	less	symptomatic,	to	pass	(Kassemi	and	Thompson	2016b).	Finally,	the	risk	for	renal	stone	development	increases	when	urinary	volume	drops	below	1.5	liters/day;	therefore,	an	effective	hydration	countermeasure	should	be	sufficient	to	produce	2.5-3	liters/day	of	urine	volume	(Kassemi	and	Thompson	2016b).		
VI.  RISK	IN	CONTEXT	OF	EXPLORATION	MISSION	SCENARIOS		Because	of	the	limitations	of	in-flight	medical	capabilities,	nephrolithiasis	during	spaceflight	could	cause	an	acute	illness	with	severe	functional	impairment,	negative	mission	impact,	or	even	significant	morbidity	or	mortality	for	the	afflicted	crewmember.	Therefore	it	is	a	critical	requirement	to	have	a	validated	countermeasure	to	prevent	renal	stone	formation	prior	to	exploration	missions.	Countermeasures	related	to	space	and	planetary	habitability	are	important;	with	respect	to	nephrolithiasis,	this	may	include	dietary	restrictions	to	reduce	risk	factors,	improved	food	science,	and	sufficient	hydration.		As	previously	mentioned,	the	primary	risk	factor	for	the	formation	of	calcium	renal	stones	in	space	is	the	hypercalcuria	induced	by	bone	atrophy	and	low	urinary	output.	Increasing	fluid	intake	and	thereby	increasing	urine	volume	can	provide	favorable	changes	in	the	
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urinary	supersaturation	of	the	stone-forming	salts.	However,	increased	urine	volume	alone	does	not	address	the	underlying	physiological	processes	that	may	exacerbate	the	in-flight	stone	risk	including	hypercalciuria,	hypocitraturia,	and	decreased	urinary	pH.		Operational	constraints,	including	supplies	of	onboard	water	and	the	busy	crew	workloads,	may	limit	the	benefits	of	hydration	to	minimize	the	risk	of	stone	formation.				Optimal	countermeasures	for	the	risk	could	mitigate	multiple	risk	factors	ranging	from	bone	atrophy	to	the	supersaturation	of	urine.	Ideally,	a	countermeasure	for	bone	atrophy	could	also	mitigate	the	risk	for	renal	stone	formation.	Research	priorities	related	to	understanding	the	time	course	of	bone	loss	and	the	influence	of	mechanical	loading,	from	post-landing	activities	as	well	as	fractional	gravity,	on	planetary	surfaces	are	relevant	to	the	risk	for	renal	stone	formation	during	exploration	missions	(Sibonga	2008).	Specific	scenarios	for	exploration	missions	are	defined	according	to	the	duration	of	time	in	space;	given	mission	duration,	location,	and	time	in	transit,	each	mission	profile	may	dictate	significant	differences	in	the	relative	risk	of	renal	stone	formation	as	well	as	the	need	for	varied	mitigation	strategies	to	address	such	risk	(Table	4).		
Table	4.		Definition	of	Exploration	Mission	Durations.	
Duration	
Length	
Mission	
Location	
Transit	time	to	
Location	(days)	
Length	of	
Stay	(days)	
Transit	time	back	
To	Earth	(days)	Short	 Moon	 3	 8	 3	Long	 Moon	 5	 170	 5	Short	 Mars	 162	 40	 162	Long	 Mars	 189	 540	 189		
Probability	Estimation	for	Renal	Stone	Event	In	the	absence	of	space	flight	incidence	of	renal	stones	in	the	U.S.	astronaut	population,	the	IMM	database	and	modeling	tool	has	been	used	to	project	an	estimation	of	the	likelihood	of	stone	occurrence	as	well	as	the	outcome	of	various	treatment	strategies.	Estimate	incidence	rates	were	generated	by	Bayesian	methods,	using	data	from	NASA’s	Lifetime	Surveillance	of	Astronaut	Health	(LSAH)	and	population	data	from	the	Centers	for	Disease	Control	(CDC)	(Litwin	and	Saigal	2012).	Due	to	this	low	occurrence,	Bayesian	methods	were	deemed	necessary	in	order	to	better	predict	probability	estimates	for	incidence	rates	of	this	medical	event.	The	Bayesian	process	allows	researchers	to	make	inferences	to	determine	the	probability	that	a	hypothesis	is	true,	conditional	on	all	available	evidence.	Information	from	these	sources	was	combined	using	a	Bayesian	update	approach	to	estimate	the	average	rate	of	stone	formation.	By	making	an	average	rate	assumption,	a	Poisson	probability	distribution	was	assumed	to	govern	the	probability	of	stone	formation.	This	model	used	only	data	pertaining	to	stone	occurrence,	not	data	related	to	blood	or	urine	chemistry.		From	the	CDC,	as	of	2004,	the	incidence	of	renal	stones	in	males	was	1-3	events	per	1000	persons	per	year	and	0.6-1	events	per	1000	persons	per	year	in	females.	For	this	spaceflight	analysis,	gender	differences	were	not	considered	since	the	vast	majority	of	astronauts	were	male;	the	resultant	average	incidence	rate	of	renal	stones	was	0.0018	per	year.	Along	with	tracking	current	and	former	astronauts,	the	LSAH	maintains	an	astronaut	control	population	database	primarily	made	up	of	NASA	Johnson	Space	Center	
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personnel.	These	data	are	of	interest	as	renal	stone	incidence	is	geographically	dependent,	due	to	factors	including	dietary	habits,	lifestyle,	and	similar;	inclusion	of	the	analog	cohort	allows	for	geographical	discrepancies	to	be	accounted	for	by	the	model.	Of	927	participants,	there	were	74	occurrences	of	renal	stones	over	17740.8	person-years,	yielding	an	incidence	rate	of	0.0042	events	per	person-year	for	this	ground-based	comparison	population	(Pietrzyk	et	al.	2007).		There	have	been	a	number	of	renal	stone	occurrences	in	the	astronaut	population,	primarily	following	short-duration	flights	as	noted	above.	At	the	time	that	this	model	was	developed,	from	a	population	of	332	astronauts	there	were	14	occurrences	over	5434.5	person-years,	yielding	an	incidence	rate	of	0.0026	events	per	person-year	(Pietrzyk	et	al.	2007).	Of	note,	this	rate	accounts	for	all	occurrences,	including	repeat	occurrences	(two	known	in	the	astronaut	population).	Approximately	40%	of	the	incidences	occurred	within	30	months	of	return-to-Earth,	and	the	remainder	occurred	after	66	months	post-return.	The	skewed	timeline	for	stone	development	may	negate	the	assumption	of	an	average	rate	for	the	entire	period	of	interest,	decreasing	the	fidelity	of	the	model.	The	total	number	of	person-years	reported	includes	the	time	frame	for	both	in-flight	and	post-flight	data.	This	process	returned	an	estimate	of	the	rate	of	renal	stone	formation	in	the	astronaut	population	(most	representative	of	post-flight	rates),	allowing	for	comparison	to	the	general	population	and	the	LSAH	control	population.	This	rate	can	be	used	as	the	input	rate	to	a	Poisson	distribution	probability	model	to	estimate	the	probability	of	renal	stone	occurrence.	The	model	predicts	a	mean	incidence	rate	of	renal	stone	formation	among	astronauts	of	0.00365	±	0.000375	events	per	person-year.	Applying	this	probability	to	the	various	proposed	NASA	missions,	the	IMM	estimated	risk	of	renal	stone	formation	for	an	individual	astronaut	as	of	2015	is	calculated	and	shown	in	Table	5.		
Table	5.		Probability	of	a	renal	stone	event	during	spaceflight	missions.	Mission	 Probability	per	person	year	of	one	or	more	in	one	crewmember	Any	Event	 Best	Case	 Worst	Case	Lunar	Sortie	(21	day)	 0.0002	(0.02%)	 0.0001	(0.01%)	 0.0001	(0.01%)	ISS	(6	month)	 0.0018	(0.18%)	 0.0011	(0.11%)	 0.0007	(0.07%)	Mars	(3	years)	 0.019	(1.90%)	 0.0066	(0.66%)	 0.0043	(0.43%)	Best	Case	Scenario	–	a	renal	stone	that	responds	to	conservative	treatment	(analgesics,	hydration)	Worst	Case	Scenario	–	a	renal	stone	that	requires	advanced	medical	intervention		These	risk	predictions	should	be	considered	very	limited	in	that	they	assume	an	average	occurrence	rate	of	renal	stones,	irrespective	of	the	stone	type	or	environmental	conditions.		Additionally,	the	inclusion	of	repeated	occurrences	could	influence	the	predicted	rate	of	incidences,	as	it	is	known	that	the	occurrence	of	one	stone	increases	the	likelihood	of	subsequent	stones.	However,	it	is	likely	a	reasonable	representation	of	the	rate	of	stone	formation	given	the	occurrence	data	available	and	given	the	assumptions	made	during	construction	of	the	estimate.	Future	models	will	include	these	data	to	improve	the	estimate	of	the	rate	of	occurrence	in	the	astronaut	corps.	More	accurate	estimates	can	be	made	with	further	analysis	of	the	periods	of	renal	stone	occurrence	in	post-flight	nephrolithiasis	cases	
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and	the	urinary	and	serum	chemistry	values	that	pertain	to	stone	formation.	The	current	model	data	will	serve	as	the	baseline	for	future	estimates	that	utilize	such	biochemical	stone	forming/inhibiting	parameters.			
VII.	MINIMIZING	THE	RISK	OF	STONE	FORMATION			
A.  Countermeasures		Nephrolithiasis	has	been	identified	by	the	IMM	as	one	of	the	leading	medical	conditions	that	would	lead	to	evacuation	of	a	crewmember	during	a	space	mission.	However,	evacuation	during	an	exploration-class	mission	to	the	moon	or	Mars	will	be	challenging,	if	at	all	possible.	Therefore,	preventive	medicine	approaches	are	necessary	in	order	to	lower	the	likelihood	and	severity	of	in-flight	renal	stone	occurrence.	Dietary	modification	and	promising	pharmacologic	treatments	may	be	used	to	reduce	the	potential	risk	of	renal	stone	formation.	Diets	low	in	oxalate	content	and	animal	proteins	may	be	advised.	Some	of	the	inhibitor	substances	are	being	considered	for	higher	risk	spaceflight	crewmembers.			Potassium	citrate,	as	described	above,	is	used	clinically	to	minimize	the	development	of	crystals	and	the	growth	of	renal	stones.	Most	orally	administered	citrate	is	metabolized	to	produce	an	alkali	load.	Administration	of	oral	citrate	increases	both	the	urinary	citrate	and	pH.	The	citrate	complexes	with	calcium,	decreasing	ion	activity,	and,	thus,	the	urinary	supersaturation	and	crystallization	of	calcium	oxalate	and	brushite.	The	increase	in	urinary	pH	decreases	calcium	ion	activity	by	increasing	calcium	complexation	to	dissociated	anions;	it	simultaneously	increases	the	ionization	of	uric	acid	to	the	more	soluble	urate	ion,	leading	to	fewer	uric	acid	stones.		Bisphosphonates	are	a	class	of	drugs	with	demonstrated	efficacy	in	treating	elderly	patients	with	osteoporosis	by	inhibiting	the	loss	of	bone.	These	agents	could	potentially	prevent	the	bone	loss	observed	in	astronauts	and	thereby	mitigate	or	avert	stone	formation,	promoting	resorptive	hypercalciuria.	One	extended	(90-day)	terrestrial	bed-rest	study	demonstrated	decreased	urinary	calcium	excretion,	alongside	decreased	supersaturation	of	calcium	oxalate	and	calcium	phosphate,	in	subjects	receiving	pamidronate	(a	bisphosphonate)	as	compared	to	controls;	there	was	a	concomitant	trend	towards	decreased	stone	formation	in	the	pamidronate	group	(Okada	et	al.	2008).	More	recently,	a	joint	study	conducted	by	NASA	and	the	Japanese	Aerospace	Exploration	Agency	evaluated	the	use	of	alendronate,	in	combination	with	resistive	exercises,	for	its	ability	to	decrease	bone	resorption	and	urinary	calcium	excretion	in	ISS	astronauts.	The	alendronate	group	demonstrated	a	trend	towards	reduced	urinary	calcium	excretion	through	flight	day	60,	and,	further,	maintained	urinary	calcium	at	pre-flight	levels	throughout	the	6-month	ISS	mission	(LeBlanc	et	al.	2013).	In	contrast	to	this,	subjects	participating	in	resistive	exercises	alone	demonstrated	a	significant	(50%)	increase	in	urinary	calcium	excretion	during	the	early	phases	of	flight;	urinary	calcium	levels	were	comparable	to	pre-flight	levels	immediately	post-flight	and	at	1-year	follow-up	(LeBlanc	et	al.	2014).	The	combination	of	bisphosphonates	and	a	resistive	exercise	regimen	appears	to	improve	bone	health	and	decrease	urinary	calcium	excretion,	and	thus	may	reduce	the	risk	of	stone	formation	during	and	possibly	after	long-duration	spaceflight.			
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B.  Renal	Stone	Risk	Assessment	U.S.	crewmembers	are	assessed	with	the	renal	stone	risk	profile	(Mission	Pharmacal,	University	of	Texas	Southwest	Laboratories,	(Mission	Pharmacal	2016)),	graphically	plotted	for	each	individual.	Although	the	urinary	risk	profile	does	not	directly	predict	the	formation	of	renal	stones,	it	illustrates	to	the	flight	surgeon	and	crewmember	the	current	urine	chemistry	environment	(Ryall	and	Marshall	1983;	Pak	et	al.	1985;	Grases	et	al.	1997;	Pak	1997).	Figures	3a	and	3b	show	example	graphs	of	the	urinary	analysis	performed.	The	graphic	provides	a	convenient	and	easily	interpretable	risk	profile	understood	by	flight	surgeons	and	crewmembers.	In	our	retrospective	review	of	cases	and	the	post-flight	renal	stone	risk	index	(RSRI)	assessment,	we	found	a	93%	correlation	between	known	stone-formers	and	a	high	RSRI.	All	but	one	case	were	found	to	have	significant	urinary	biochemical	abnormalities	in	the	stone	risk	profile;	the	one	outlying	case	had	minor	abnormalities.	There	were	some	false	positives	in	prospective	cases,	confounded	by	urine	collection	biases,	but	there	were	no	false	negatives.			The	risk	profile,	considered	in	conjunction	with	the	lifestyle	and	dietary	habits	of	the	individual,	can	be	a	valuable	monitoring	and	education	tool	(Rivers	et	al.	2000).	Individuals	who	are	at	an	increased	risk	or	have	previously	formed	renal	stones	can	be	followed,	patient	compliance	can	be	assessed,	and	the	effectiveness	of	medical	treatment	can	be	determined	with	this	profile.	The	renal	stone	risk	profile	has	proven	value	in	the	clinical	setting	as	a	tool	for	classifying	patients	according	to	the	etiology	of	the	formation	of	their	renal	stones	(Pak	et	al.	1985;	Yagisawa	et	al.	1998;	Lifshitz	et	al.	1999).	Further,	the	relatively	low	cost	of	the	renal	stone	risk	profile	makes	this	a	cost-effective	methodology,	and	may	mitigate	both	the	risk	of	developing	a	stone	in-flight	and	the	potential	mission	impact	if	nephrolithiasis	occurs.	Clinical	and	research	experience	has	shown	that	monitoring	the	urinary	environment	and	estimating	the	risk	for	renal	stone	development	can	lead	to	significantly	improved	control	of	stone	disease	when	this	information	is	used	to	guide	medical	therapy	(Morgan	and	Pearle	2016),	and	the	need	for	surgical	intervention	and	stone	removal	can	be	dramatically	reduced	by	an	effective	prophylactic	program.	Studies	have	concluded	that,	for	terrestrial	stone-formers,	the	reproducibility	of	urinary	stone	risk	factor	analyses	is	satisfactory	in	repeat	urine	samples	and	a	single	stone	risk	analysis	is	sufficient	for	a	simplified	medical	evaluation	of	urolithiasis	(Pak	et	al.	2001).	The	accuracy	of	measuring	urinary	stone	promoter-	and	inhibitor-substances	is	improved	by	including	matrix	components,	uroproteins,	uromucoid,	and	glycosaminoglycans	in	the	analysis	(Batinić	et	al.	2000).	Other	laboratory	analyses	for	urinary	stones	include	blood	urea	nitrogen,	serum	electrolytes,	creatinine,	calcium,	uric	acid,	and	phosphorous.			As	applied	to	the	U.S.	space	program,	this	health	care	monitoring	program	may	provide	several	distinct	advantages.	Crewmembers	with	an	increased	baseline	risk	prior	to	spaceflight	will	further	increase	their	risk	of	stone	formation	when	exposed	to	the	microgravity	environment	and	the	resultant	bone	loss,	hypercalciuria,	increased	urinary	sodium,	and	decreased	urinary	output.	The	RSRI	evaluation	may	identify	the	risk	prior	to	flight,	help	to	identify	appropriate	medical	intervention,	and	reduce	the	potential	risk	before,	during,	and	after	spaceflight.	In	implementing	the	schedule	of	RSRI	measurement	with	24h	urine	collection,	it	was	determined	that	all	astronauts	should	have	an	annual	assessment	dedicated	to	stone	risk	factor	identification.	Space	Shuttle	crewmembers	with	
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significant	risk	factors	or	history	of	previous	calculi	also	had	pre-flight	evaluations	for	stones.	Currently,	this	assessment	is	performed	annually	as	well	as	post-flight,	during	the	comprehensive	medical	examination,	performed	twice	at	3	and	30	days	after	return	in	all	crews.		Pre-flight	and	post-flight	renal	stone	risk	profiles	continue	to	be	conducted	as	a	medical	requirement	for	all	ISS	crewmembers.	Additional	research	studies	are	currently	collecting	urine	samples	for	biochemical	analyses	to	identify	changes	in	the	urinary	biochemistry	that	potentially	increase	the	risk	of	stone	formation.	Together	these	data	will	provide	an	indicator	of	the	impact	of	dietary	factors,	hydration	status,	and	microgravity	exposure	for	stone	development.	The	urinary	biochemical	data	are	further	employed	to	improve	the	modelling	of	stone	formation	risk	and	the	potential	to	enhance	the	predictive	power	of	these	models.		
C.  In-flight	Prevention	During	a	mission,	crewmembers	follow	procedures	that	prevent	the	growth	of	stones.	In	particular,	taking	oral	fluids	in	amounts	sufficient	to	maintain	adequate	hydration	is	encouraged.	If	an	astronaut	is	suffering	from	severe	space	motion	sickness	early	in	flight,	intravenous	fluids	may	be	considered	to	guard	against	dehydration;	to	date,	this	intervention	has	not	been	required.	In	addition	to	hydration,	sodium	consumption	should	be	limited	during	flight.	As	previously	noted,	potassium	citrate	or	potassium-magnesium	citrate	may	be	useful	countermeasures	to	stone	formation	in	certain	high-risk	individuals.			
D.  In-flight	Diagnosis	and	Monitoring		Ultrasound	imaging	technology	is	available	to	the	crews	on	the	ISS.	If	symptoms	suggesting	nephrolithiasis	occur	in	flight,	spaceflight	crews	can	take	specific	steps	to	respond	and	mitigate	further	risk,	including	the	use	of	sonographic	imaging.	The	onboard	crew	medical	officer,	with	guidance	from	ground	medical	specialists,	is	able	to	monitor	an	affected	crewmember’s	vital	signs,	hydration	status,	and	clinical	appearance,	and	may	perform	an	ultrasound	exam	with	real-time	guidance	from	ground	controllers.	Guided	ultrasound	examinations	have	been	performed	many	times	for	investigational	purposes	and	shown	to	provide	adequate	diagnostic	imagery	(Sargsyan	et	al.	2005;	Jones	et	al.	2009).	The	anatomic	content	and	fidelity	of	the	images	captured	in	these	studies	were	excellent	and	sufficient	for	clinical	decision	making,	comparable	to	imaging	obtained	under	terrestrial	conditions.	In	the	case	of	an	acute	renal	stone	event,	image	characterization	would	allow	for	stone	localization	and	estimation	of	size,	data	that	could	prove	critical	to	medical	decision-making.		
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	Figure	4.	Ultrasound	image	showing	capability	to	detect	a	renal	stone	less	than	3	mm.		For	 example,	 ultrasound	 may	 be	 used	 to	 show	 visible	 calculi	 in	 the	 ureteropelvic	junction	 or	 renal	 pelvis,	 and	 can	 further	 identify	 unilateral	 distension	 of	 the	 collecting	system	from	either	hydronephrosis	or	hydroureter	if	adequate	time	has	passed	to	allow	for	distention	 to	 occur.	 Ultrasound	 may	 also	 show	 loss	 of	 the	 ureteral	 jet	 in	 the	 bladder	ipsilateral	to	the	side	of	pain,	further	supporting	a	clinical	diagnosis	of	nephrolithiasis.	 
	
VIII. GAPS	The	following	section	raises	relevant	implementation	issues	and	knowledge	gaps	associated	with	mitigating	renal	stone	formation	in	the	context	of	the	current	exploration	mission	scenarios	and	the	operational	constraints	of	power,	mass,	volume,	time	and	expense.	At	the	time	of	writing,	7	research	knowledge	gaps	have	been	identified	that	are	directly	related	to	the	Risk	of	Renal	Stone	Formation.	These	are:		
• B5	-	What	is	the	current	state	of	knowledge	regarding	renal	stone	formation	due	to			 		spaceflight?	
• N13	-	Can	renal	stone	risk	be	decreased	using	nutritional	countermeasures?	
• B6	-	What	are	the	contributing	factors	other	than	loss	of	bone	mineral	density?	
• B7	-	Is	it	necessary	to	increase	crew	fluid	intake	and,	if	possible,	to	what	extent	will	it	mitigate	stone	formation?	
• B8	-	Do	pharmaceuticals	work	effectively	in	spaceflight	to	prevent	renal	stones?	
• B9	-	What	is	the	frequency	of	post-flight	stone	formation;	the	incidence	and	types	of	stones;	and	the	time	course	of	stone	formation?	How	does	stone	formation	correlate	with	food	intake	and	hydration	status?	
• B16	-	Can	inhibitors	of	stone	formation	be	sufficiently	provided	through	dietary	sources?		
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Current	Status	of	Gap	Knowledge		Medical	records	are	reviewed	for	individual	crewmembers	to	identify	renal	stones	events.	The	database	of	stone	events	is	presented	annually	to	the	JSC	Human	Systems	Risk	Board	(HSRB)	characterizing	the	number	of	events	and	time	of	the	event.			To	assess	the	risk	of	stone	formation	due	to	spaceflight,	postflight	ultrasound	was	begun	in	February	2016.	The	imaging	is	scheduled	to	occur	within	30	days	of	the	crewmember’s	landing.	At	this	time	58	ultrasound	exams	have	been	completed	on	49	crewmembers	including	2	preflight	and	4	postflight.	The	review	of	these	images	is	in	medical	review	with	a	summary	of	the	results	to	be	presented	to	the	HSRB.	The	postflight	ultrasounds	will	provide	initial	evidence	for	in-flight	renal	stone	formation.		Preflight	and	postflight	renal	stone	risk	profiles	continue	to	be	conducted	as	a	medical	requirement	on	all	ISS	crewmembers.	Additional	research	studies	are	collecting	urine	samples	for	biochemical	analyses	identifying	changes	in	the	urinary	biochemistry	potentially	increasing	the	risk	of	stone	formation.	Together	these	data	will	provide	an	indicator	of	the	impact	of	dietary	factors,	hydration	status	and	microgravity	exposure	for	stone	development.	The	urinary	biochemical	data	are	also	being	employed	to	improve	the	modelling	of	stone	formation	and	the	potential	to	enhance	the	predictive	power	of	these	models.		
IX.  CONCLUSIONS	NASA’s	strategic	goals	are	for	a	human	presence	for	exploration-class	missions,	which	include	the	goals	of	returning	to	the	moon	and	landing	on	Mars.	With	these	objectives,	exploration	crewmembers	will	experience	extended	exposure	to	the	unique	environments	of	space	and	the	adaptive	effects	of	human	physiology	to	microgravity,	partial	gravity,	and	to	the	operational	constraints	and	limitations	of	space	habitation.	The	adaptive	effects	of	space	travel	on	human	physiology	result	in	altered	urinary	chemical	composition	that	occurs	both	during	spaceflight	and	after	return	to	Earth,	resulting	in	known	risk	factors	for	the	formation	of	renal	stones.	As	of	2016,	37	known	symptomatic	medical	events	consistent	with	urinary	calculi	have	been	experienced	by	U.S.	astronauts.	Although	previous	stone	formers	are	at	high	risk	to	form	new	stones,	it	is	not	possible	to	predict	which	crewmembers	will	form	renal	stones	de	novo	on	Earth	or	during	space	missions.		Thus,	efforts	should	continue	to	define	the	risk	of	renal	stone	formation	in	space	with	countermeasures	focused	on	the	prevention	of	stone	formation.			
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